Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

21%
Genetic Cohort Participants
Enrollmen Goal: 600

17%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment Goal: 400

100%
Control Participants
Enrollment Goal: 200

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment Goal: 100

Last Update: April 6, 2015

 

More about study cohorts >

Welcome

Welcome to the Parkinson’s Progression Markers Initiative (PPMI), a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

PPMI at AAN 2015

PPMI is headed to the American Academy of Neurology (AAN) 2015 Annual Meeting, taking place in Washington D.C. from April 18 through April 25. Top players in neurology will come together to learn about the latest in research, showcased through presentations and posters, including several featuring PPMI data.


Whole Exome Sequencing Data Now Available

The PPMI Genetics Core has just made their whole exome sequencing data live in the PPMI database. This sequencing targeted 201,121 Exons, UTRs, and miRNA in DNA from whole-blood from the original PPMI cohort of over 600 PD, SWEDD, and control subjects. Read more about the analysis and learn how to access the data.


Dr. Ken Marek’s Presentation for Enrolled Participants Posted

PPMI Principal Investigator, Dr. Ken Marek: “We have made a great deal of progress in the study, largely thanks to the persistence of the sites, of the investigators, and, most importantly, of the participants.” Listen to Marek’s full presentation.


Reform Movement and The Michael J. Fox Foundation Team Up for Study Investigating Genetic Mutations Common in Jews

Religious Action Center of Reform Judaism Director Rabbi Jonah Pesner: “This study provides an important opportunity to help potentially stamp out an insidious disease and reflects the Jewish imperative toward pikuach nefesh, the saving of a life.”


PPMI Expands to Include Individuals with GBA Mutation

PPMI will now be following individuals with a GBA mutation as part of the Genetic Cohort. In addition to being linked to Parkinson’s disease, GBA mutations can cause Gaucher disease. A GBA mutation is more common among certain populations, specifically those of Ashkenazi (Eastern European) Jewish descent. Read the full press release here.


Learn More